NewBiotics, Inc. develops pharmaceutical drugs to treat cancer and infectious disease. It applies its Enzyme Catalyzed Therapeutic Activation technology to develop pharmaceuticals that transform drug resistance into therapeutic advantage. The company was founded by H. Michael Shepard and Geoffrey Myles Wahl in 1997 and is headquartered in San Diego, CA.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Pantheco A/S is a Danish biotech company, whose mission it is to develop drugs based upon Peptide Nucleic Acid (PNA) for the treatment of infectious diseases caused by resistant microorganisms. Pantheco represents a spin-off of the research activities and know-how within the Peptide Nucleic Acid (PNA) antisense technology invented at University of Copenhagen in 1992 and the PNA Patent Rights licensed from Isis Pharmaceuticals, Inc. in US. By employing the PNA technology, chemistry, know-how, and the exclusive rights for human therapeutic uses within anti-infectives, Pantheco has the unique opportunity to generate novel classes of anti-infective drugs and become a world class leader within novel generations of antisense therapeutics.

Focus Technology Co., Ltd. provides electronic commerce platform and comprehensive trade services. It also offers Internet insurance, supply chain management, business incubation, Internet technology development and application, computer software and hardware development, technology import and export, business-to-business platforms, and cross-border trade services. The company was founded by Jin Hua Shen on January 9, 1996 and is headquartered in Nanjing, China.

Merck (d.b.a. EMD Millipore in the U.S. and Canada) is a German chemical and pharmaceutical company. Merck, also known as “German Merck” and “Merck Darmstadt”, was founded in Darmstadt, Germany, in 1668, making it the world's oldest operating chemical and pharmaceutical company. The company was privately owned until going public in 1995. However, the Merck family still controls a majority (≈70%) of the company's shares. Following World War I, Merck lost possession of its foreign sites, including the Merck & Co. subsidiary in the United States. Merck & Co., which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, is now an independent company. Merck KGaA operates mainly in Europe, Africa, Asia, Oceania and Latin America. Since Merck & Co. holds the rights to the Merck name in the U.S. and Canada, the company operated under the umbrella brand EMD Chemicals in North America, and since 2010 as EMD Millipore (after the acquisition of Millipore Corporation), formed from the initials of Emanuel Merck, Darmstadt. Founded in 1668 in Darmstadt, Merck KGaA of Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The success of the export business to the United States led in 1887 to the establishment of an office in New York, which gave rise to their subsidiary [Merck & Co.](http://www.crunchbase.com/organization/merck-co-inc) four years later. Owing to World War I, Merck & Co. was expropriated in 1917. The two companies have been separate every since. Merck KGaA Subsidiaries: - [Merck Consumer Healthcare](http://www.crunchbase.com/organization/merck-consumer-healthcare) - [Merck Performance Materials](http://www.crunchbase.com/organization/merck-performance-materials)

Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.

bredent Medical GmbH & Co. KG is a German private company located in Senden. The firm develops and manufactures dental implants. Gerald Micko and Peter Brehm are the current co-CEOs of the company.

Chongqing Boer Animal Pharmaceutical Co., Ltd. (Boer Veterinary Medicine) is a national high-tech enterprise under the British Bull International Pharmaceutical Co., Ltd. Its brother company is Chongqing Boer Biological Medicine Co., Ltd. Boer Veterinary Medicine is a large GMP enterprise specializing in the international production of animal health drugs, integrating scientific research, development, production, sales and service. In 2012, it successfully passed the GMP certification of veterinary drugs issued by the Ministry of Agriculture of the People's Republic of China. At present, it can produce nearly 100 varieties of 9 dosage forms, including small volume water injection, large volume non intravenous injection, oral liquid, granules, tablets, powders, powders, premixes, powder injections, etc, More than 40 products have obtained the global free sales license, which can meet the needs of users at different levels. In 2013, the BULLVET trademark obtained the registration certificate from the State Administration for Industry and Commerce, and then was registered in 45 countries around the world. At present, it has obtained the registration license from the European Union, Japan, Canada and Australia; In 2014, the products entered 22 countries in the world, and 10 countries are under registration; At present, the company maintains good trade relations with Saudi Arabia, Egypt, Jordan, Chile, Nigeria, Sudan, Tanzania and other countries.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Beijing Union Pharmaceutical Second Factory Co., Ltd., established on 1993-05-18, Business scope includes licensed projects:pharmaceutical production;Cosmetic production[Branch operation].(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Import and export;Technology Import and Export;Import and export agency;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Zhuhai Solida Medical Equipment Co., Ltd., established on 2010-06-18, Business scope includes medical devices,Medical Consumables,medicine,Biological product,Healthy food,cosmetic,food,daily necessities,hygiene products,Labor protection supplies,Production of disinfection products, etc.,operate(wholesale,retail)and import and export trade;technology R & D,technical consulting,Environmental cleaning and disinfection and other technical services and brand planning.Scope of medical device business license:Class III6807Thoracic Cardiovascular Surgery Instruments,6808Abdominal Surgery Instruments,6812Surgical Instruments for Obstetrics and Gynecology,6813Family Planning Surgical Instruments,6821Medical electronic equipment,6822Medical Optics,Instruments and endoscopic equipment(Except for contact lenses and care solutions),6823Medical Ultrasonic Instruments and Related Equipment,6824Medical laser equipment,6840Clinical Laboratory Analytical Instruments(Except for in vitro diagnostic reagents),6854operating room,emergency room,Consulting room equipment and appliances(The license is valid until2024year11moon19day).Scope of medical device production license:Class II medical device:6812Surgical Instruments for Obstetrics and Gynecology,Class II6821Medical electronic equipment,Class II:6826Physiotherapy and Rehabilitation Equipment,Class II6854operating room,emergency room,Consulting room equipment and appliances,Class II6840Clinical Laboratory Analytical Instruments(The license is valid until2021year4moon26day),IIkind6857Disinfection and sterilization equipment and utensils,IIkind,IIIkind6866Medical polymer materials and products,IIkind,IIIkind6864Medical hygiene materials and dressings.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)according to<Zhuhai Special Economic Zone Commercial Registration Regulations>,The scope of business is not a registration item.The above business scope information is provided by the commercial entity,The commercial subject's authenticity of the information,responsible for legality:(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Qingdao Weiliao Medical Biomaterials Co., Ltd., established on 2013-01-14, Business scope includes Ι class,Class II,Research and development of Class III medical devices and disinfection products,production and sales;biological reagent,biologics,Research and Development of Biomaterials,Technical Consulting and Services;Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

FUJIFILM Toyama Chemical Co. Ltd., a subsidiary of FUJIFILM Holdings Corp., is a Japanese company located in Tokyo that develops and manufactures radioactive medical supplies. It was founded in 1968. Misao Tsuda is currently the CEO of the firm. FUJIFILM Toyama Chemical Co. Ltd. was acquired by FUJIFILM Holdings Corp. from Daiichi Sankyo Co., Ltd. on October 01, 2006.

Sichuan Oufen Polar Health Management Co., Ltd., established on 2019-04-18, Business scope includes licensed projects:The second type of value-added telecommunications services;Food Internet Sales;Internet information service;food sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Health Consulting Services(Does not include medical services);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export;Cosmetics Retail;Personal Hygiene Sales;Stationery retail;Sporting Goods and Equipment Retailing;Daily necessities sales;Chemical product sales(No licensed chemical products);Feed Raw Material Sales;Business Management Consulting;Non-residential real estate leases;internet sales(Except for products that require a license for sale);Socioeconomic Advisory Services;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Healthy food(prepackaged)Sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).